Manage Your Liver
Q:

New research finding: New hepatitis C antiviral drugs increase the risk of liver cancer

New research finding: New hepatitis C antiviral drugs increase the risk of liver cancer
A:

A study published in the International Liver Congress in 2016 [1] came up with a shocking and unexpected result: Patients with hepatitis c and cirrhosis who use direct antiviral agents (DAA) may begin to develop liver cancer within 2 weeks. Leading researcher Stefano Brillianti, MD stated “The hypothesis is that immune surveillance may be reduced too rapidly,” and “You have an immediate drop in viremia, but also attenuation of inflammation.”

 

The study indicated that patients with a history of hepatocellular carcinoma (liver cancer) have the highest risk of developing tumor after receiving direct-acting antiviral therapy, in addition, the progression is very fast. "Patients with previous hepatocellular carcinoma are, of course, at risk of recurrence anyway," Dr Brillianti said. ”A 30% rate over 3 years from initial surgery or ablation is normal. What was surprising to us was that we were observing 4 cm lesions after 12 weeks." [2]

 

Another research conducted by the University of Barcelona found that out of 58 hepatitis C patients with a history of hepatocellular carcinoma (with complete radiologic response), 55 were cirrhotic before starting direct-acting antiviral therapy. After a median follow-up of 5.7 months, the rate of tumor recurrence was 27.6%, with a median time to recurrence of 3.5 months. This research echoes with the previously mentioned, and suggests that patients with hepatitis C should be closely monitored after treatment with direct-acting antivirals. [3]

 

Stefano Brillanti, MD, went on to say, "This (liver cancer) is a different cancer  than elsewhere in oncology — it is a cancer within an advanced chronic disease — so the prognosis, the life expectancy, is related not only to the liver cancer but also to the liver disease and liver function,”. He added, "If you don't treat these patients and ameliorate their liver function, and if hepatocellular carcinoma occurs, you have no chance of curing them. But if you ameliorate liver function and they develop hepatocellular carcinoma, you can cure it better because their improved liver function will allow an ablation.”

 

These two latest research studies once again prove that is it vital to stop inflammation in the liver, and to ensure normal liver function. Whether it is before or after treatment, both hepatitis C patients and patients with hepatocellular carcinoma history should set this as their main objective. Otherwise, even if the virus is successfully removed from the body, normal liver function cannot be guaranteed.

Disclaimer:
  • * All research and clinical data should be used as reference purposes only, results may vary.
Related Questions
A:
For years we have known that there is a strong link between obesity and liver cancer, and it is possibly due to the high fat content in the body. And because of this, people with obesity are often considered at risk for liver cancer. A recent research conducted by Monash University and the Peter MacCallum Cancer Centre in Australia confirms that obese people are at risk for liver cancer, but based on an entirely different reason.   The new finding
A:
If you know someone who is diagnosed with more advanced stages of liver disease, then you might have heard of the term MELD score. MELD refers to the model for end-stage liver disease. It is a scoring system that shows how urgently a patient needs a liver transplant. Since MELD score is often used as a way to predict a patient’s prognosis, many patients try hard to improve their score in the hope of better health. Before we move on to the discussion of how MELD score
Hit Questions
A:
The liver carries out essential functions, including detoxifying harmful substances in your body, cleaning your blood and making new blood and other vital nutrients. Cirrhosis is scarring of the liver caused by long-term liver damage. The loss of liver cells turns into scar tissue which prevents the liver working normally, reducing or in some cases, completely losing liver function. Cirrhosis is a long-term chronic liver damage; it is often caused by chronic live
A:
ALT (Alanine Aminotransferase / SGPT) is a type of enzyme found in liver cells. When the liver cells are functioning normally, the ALT enzymes should be contained within the liver cells.    You can imagine each liver cells as a balloon, and the ALT enzymes are the air inside the balloon. When the balloon is damaged, the air will be released. And when the liver cells is damaged, ALT enzymes are released into the bloodstream, therefore we are able to find out the l
A:
ALT (Alanine Aminotransferase / SGPT) is an enzyme that is mainly found in liver cells. The level of ALT in our bloodstream is the primary indicator of liver health.   What does high ALT indicate? ALT enzymes are normally contained within liver cells when the liver is healthy, but when the liver cells are injured or damaged by whatever means, ALT enzymes are released into the bloodstream, causing levels to go up. Therefore, by measuring the
A:
Fibrosis is scarring of the liver that results from chronic inflammation. It is a process where the damaged, dying liver cells are replaced by fibrous scar tissue, causing the liver to become hard. The extent of liver fibrosis can vary, and it is often classified in several stages. The most common classification is a scale from F0 to F4. F0 indicates no fibrosis. A normal liver is at a stage between F0 and F1. F2 denotes light fibrosis, and F3 indicates severe fibrosis. When scar tissue build
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Have Questions?
Sumbit your question to us for profeessional answers!
Looking for help? Ask our customer support team!
Contact Us
Subscribe To Our Mailing List And
Never Miss Another Great Promotion!
Join our mailing list to receive latest new about our company, plus health articles. You will also be able to receive early bird discount from us!
Maybe Later, Thank you.
Subscribe success! You will receive latest new soon.